USAISR Burn Center
San Antonio, Texas, 78234, United States
NCT Number: NCT06628037
This study will examine the tolerability of a gel formulation of the enzyme SN514 in patients with burns suitable for enzymatic debridement. In a rising dose fashion by sequential cohort, concentrations of 0.1%, 0.2%, 0.4% and 0.8% will be tested. Groups of 3 will undergo daily debridement for up to 7 days. Extent of debridement and adverse signs and symptoms will be recorded daily. Dose escalation will stop if a dose level is found to be intolerable. Dose escalation may accelerate if a tested dose is entirely ineffective. There is no placebo control as all burn wounds require debridement.
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Phase 1 / Phase 2
San Antonio, Texas, 78234, United States
The design of the study is a sequential rising dose to the maximum tolerated dose, in which each subject will be exposed to only one concentration of the test article. Dose limiting toxicities are defined as "Severe" or CTCAE v5 Grade 3 or higher adverse events. This study in burn patients is designed to apply SN514-066b over 25 cm2 (0.14% TBSA for a 1.73 m2 adult) up to 500 cm2 (2.9%), at sequentially rising concentrations of 0.1%, 0.2%, 0.4% and 0.8% (< 1.0 mg/cm2). The highest exposure would be 0.8% (8 g per 100 cc of gel) over 2.9% of 1.73 m2 = 800 mg or 11.4 mg/kg applied topically (70 kg patient).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Main Inclusion Criteria:
Main Exclusion Criteria:
Enzyme debrider
Time frame: Daily x 7days
Number of participants with treatment-related adverse events of Grade 3 or higher as assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0, where a higher grade on the scale of 1 to 5 is a worse outcome.
Time frame: Daily x 7days
Percent of eschar removed following each 24 hr debridement
Time frame: Daily x 7days
Changes from baseline to end of treatment in blood levels of C-reactive protein (CRP) in mg/dL, serum tryptase in ng/mL, and total complement activity (CH50) level in hemolytic units.
Time frame: Daily x 7days
Record daily the appearance of new, spreading or darkening redness of the treated or adjacent tissue
Time frame: Daily for 7 days
Observe daily for the appearance of purulent material in the treatment area
SERDA bv
Industry
A Phase 1 Maximum Tolerated Dose Study of SN514-066b in Adult Patients With Deep Partial Thickness Dermal Burns
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07566923
Anxiety Disorders, Burn Injury
Istanbul, Kartal, Turkey (Türkiye)
View Trial DetailsNCT07577960
Burn Injury, Burns
Istanbul, Kartal, Turkey (Türkiye)
View Trial DetailsNCT07566871
Anxiety Disorders, Burn Injury
Istanbul, Kartal, Turkey (Türkiye)
View Trial DetailsNCT07566910
Anxiety Disorders, Burn Injury
Istanbul, Kartal, Turkey (Türkiye)
View Trial Details